HeyPsych
ConditionsTreatmentsToolsFind CareFor Clinicians

If you're in crisis, help is available 24/7

Call or text 988|More resources
HeyPsych

Better mental health starts with better decisions.

Clinical content reviewed by mental health professionals.

Explore

  • Conditions
  • Treatments
  • Tools
  • Find Care

Resources

  • Knowledge Hub
  • Assessments
  • For Clinicians

Company

  • About
  • Privacy
  • Terms
  • Contact

© 2026 HeyPsych. All rights reserved.

HeyPsych provides decision-support information. Not a substitute for professional medical advice.

Fecal Microbiota Transplantation (FMT)

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published September 4, 2026•Updated September 4, 2026•Reviewed September 4, 2026

Indications

Primary Indications

Recurrent CDI (approved indication)Exploratory use in depression, autism, and Parkinson’s disease

Mechanism

FMT restores gut microbial diversity, improves intestinal barrier function, and modulates immune and neuroendocrine pathways. Through the gut–brain axis, these changes may influence neurotransmission, inflammation, and behavior.

Protocol

Preparation

Donor stool screened extensively for pathogens. Recipient may undergo bowel preparation depending on delivery route.

Procedure

  1. Stool processed and filtered into liquid suspension or freeze-dried capsules
  2. Administered via colonoscopy, enema, nasoenteric tube, or oral capsules

Frequency: Single dose or repeated sessions depending on indication

Duration: Single treatment or multiple treatments over weeks

Total Treatment Time: Procedure plus follow-up monitoring

Equipment

  • Donor stool preparation system
  • Colonoscopy or nasoenteric delivery equipment
  • Encapsulation system for oral delivery

Session Structure

Pre-Session

Donor screening, recipient preparation (including possible antibiotics or bowel prep).

Treatment Phase

Administration of processed donor microbiota via chosen route.

Post-Session

Monitoring for gastrointestinal or infectious complications.

Expected Outcomes

Immediate

  • Gastrointestinal upset possible (diarrhea, cramping)

Short Term

  • Resolution of CDI
  • Potential improvements in psychiatric or neurological symptoms (under investigation)

Long Term

  • Sustained gut microbiome diversity
  • Possible long-term behavioral or neurological benefit (uncertain)

Side Effects

common

  • Diarrhea
  • Abdominal cramping
  • Bloating

uncommon

  • Transient fever
  • Constipation

rare

  • Transmission of infection
  • Sepsis in immunocompromised patients

Contraindications

absolute

  • Severe immunosuppression
  • Unscreened donor stool

relative

  • Active GI infection
  • Significant comorbidities increasing procedural risk

Patient Selection

ideal candidates

  • Patients with recurrent CDI
  • Research participants with psychiatric or neurological disorders

screening required

  • Donor pathogen screening
  • Recipient infectious disease evaluation

Training Requirements

practitioner

  • Gastroenterologist
  • Infectious disease specialist

facility

  • Hospital or clinic with endoscopy or investigational capability

Research Evidence

Key Studies

  • Kang DW, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10.
  • Xie WR, et al. Fecal microbiota transplantation for major depressive disorder: a pilot randomized clinical trial. J Affect Disord. 2022;302:11–21.

Limitations

Heterogeneity of donor samples, small sample sizes, lack of standardized protocols.

Cost Considerations

typical session cost: $1,500–$5,000 depending on delivery route

total treatment cost: Varies based on number of sessions and facility

insurance coverage: Typically covered for recurrent CDI; not for psychiatric or neurological use

cost effectiveness: High for recurrent CDI; unproven for other indications

ux display: undefined

collapsible: undefined

heading: undefined

Integration Support

Concurrent Therapies

  • Antibiotics (for CDI)
  • Psychiatric medications
  • Behavioral therapies

Special Populations

Clinical Notes

  • Donor screening is critical for safety.
  • Long-term psychiatric and neurological benefits remain unproven.
  • Capsulized formulations may improve accessibility and acceptability.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists